Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE-AKI: SP16 for prevention of cardiac surgery-associated acute kidney injury in CKD
2025-522491-89-00Phase 2Authorised
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney failure (AKF), chronic kidney disease (CKD), cardiac morbidity and 1 more comparing SP16-3M with Placebo (2 arms). Planned start Sep 2026; status: authorised.
02
Drugs
SP16-3M
03
Conditions
acute kidney failure (AKF)chronic kidney disease (CKD)cardiac morbidityCardiac valve disease (VHD)
Beyond the preview
Go deeper on 2025-522491-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522491-89-00.